Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Stereotactic body radiation therapy for liver metastasis - The linac-based Greater Poland Cancer Centre practice.

Fundowicz M, Adamczyk M, Kołodziej-Dybaś A.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):158-162. doi: 10.1016/j.rpor.2017.02.008. Epub 2017 Apr 4.


Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy.

Méndez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, IJzermans JNM, Verhoef C.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):126-131. doi: 10.1016/j.rpor.2016.10.003. Epub 2016 Dec 2.


Radiobiology of stereotactic body radiation therapy (SBRT).

Macià I Garau M.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):86-95. doi: 10.1016/j.rpor.2017.02.010. Epub 2017 Mar 23. Review.


Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).

Dervenis C, Xynos E, Sotiropoulos G, Gouvas N, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Kountourakis P, Kyriazanos I, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Ziras N, Souglakos J.

Ann Gastroenterol. 2016 Oct-Dec;29(4):390-416. Epub 2016 Jun 3.


A single reference measurement can predict liver tumor motion during respiration.

Cvek J, Knybel L, Molenda L, Otahal B, Jonszta T, Czerny D, Feltl D.

Rep Pract Oncol Radiother. 2016 May-Jun;21(3):278-83. doi: 10.1016/j.rpor.2015.11.003. Epub 2015 Dec 29.


Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation.

Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US.

Front Oncol. 2016 Jun 20;6:141. doi: 10.3389/fonc.2016.00141. eCollection 2016. Review.


Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.

Andratschke N, Parys A, Stadtfeld S, Wurster S, Huttenlocher S, Imhoff D, Yildirim M, Rades D, Rödel CM, Dunst J, Hildebrandt G, Blanck O.

Radiat Oncol. 2016 May 28;11:74. doi: 10.1186/s13014-016-0652-4.


Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.

Kim JW, Seong J, Lee IJ, Woo JY, Han KH.

Oncotarget. 2016 Jun 28;7(26):40756-40766. doi: 10.18632/oncotarget.9450.


Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.

Takeda A, Sanuki N, Tsurugai Y, Oku Y, Aoki Y.

J Radiat Res. 2016 Jul;57(4):400-5. doi: 10.1093/jrr/rrw029. Epub 2016 Mar 16.


Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions.

Bae SH, Kim MS, Jang WI, Cho CK, Yoo HJ, Kim KB, Han CJ, Park SC, Lee DH.

J Korean Med Sci. 2015 Aug;30(8):1055-61. doi: 10.3346/jkms.2015.30.8.1055. Epub 2015 Jul 15.


A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases.

Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R.

Ann Surg Oncol. 2016 Jan;23(1):218-24. doi: 10.1245/s10434-015-4579-z. Epub 2015 May 12.


Stereotactic radiation therapy for liver metastases: factors affecting local control and survival.

Andratschke NH, Nieder C, Heppt F, Molls M, Zimmermann F.

Radiat Oncol. 2015 Mar 20;10:69. doi: 10.1186/s13014-015-0369-9.


Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection.

Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):837-42. doi: 10.1016/j.ijrobp.2015.01.036. Epub 2015 Mar 30.


Minimally invasive local therapies for liver cancer.

Li D, Kang J, Golas BJ, Yeung VW, Madoff DC.

Cancer Biol Med. 2014 Dec;11(4):217-36. doi: 10.7497/j.issn.2095-3941.2014.04.001. Review.


Oligometastasis and oligo-recurrence: more than a mirage.

Huang F, Wu G, Yang K.

Radiat Oncol. 2014 Oct 31;9:230. doi: 10.1186/s13014-014-0230-6. Review.


Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

Timmerman RD, Herman J, Cho LC.

J Clin Oncol. 2014 Sep 10;32(26):2847-54. doi: 10.1200/JCO.2014.55.4675. Epub 2014 Aug 11. Review.


Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases.

Yuan ZY, Meng MB, Liu CL, Wang HH, Jiang C, Song YC, Zhuang HQ, Yang D, Wang JS, Wei W, Li FT, Zhao LJ, Wang P.

Onco Targets Ther. 2014 Jun 12;7:915-23. doi: 10.2147/OTT.S58409. eCollection 2014.


Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients.

Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsuo Y, Nomiya T, Nakagawa K; Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG)..

Radiat Oncol. 2014 May 10;9:112. doi: 10.1186/1748-717X-9-112.


Stereotactic ablative radiotherapy for oligometastatic disease in liver.

Kim M, Son SH, Won YK, Kay CS.

Biomed Res Int. 2014;2014:340478. doi: 10.1155/2014/340478. Epub 2014 Apr 29. Review.


Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.

Takeda A, Sanuki N, Kunieda E.

World J Gastroenterol. 2014 Apr 21;20(15):4220-9. doi: 10.3748/wjg.v20.i15.4220. Review.

Supplemental Content

Support Center